Achieve consistent, long-term IOP control in cases of advanced and complex glaucoma
Implanted in thousands of patients worldwide, the Molteno3® Glaucoma Drainage Device has been clinically validated to deliver consistent, long-term reduction in intraocular pressure (IOP) in cases of advanced or complex glaucoma.1
1. Molteno ACB, et al. Long-Term Results of Primary Trabeculectomies and Molteno Implants for Primary Open-Angle Glaucoma. 2011. Arch Ophthalmol; 129(11):1444 – 1450
“One of the coolest things about the Molteno3® is its efficiency. It’s a true single quadrant surgery. There’s no muscle involvement and so you don’t have to worry about dissecting the muscles or using muscle hooks.”
A History of Innovation
Molteno3® is the culmination of more than 50 years of research and development. First introduced in 1966, the Molteno3® glaucoma drainage device reflects a history of extensive research into bleb formation and function – and is considered to be the gold standard in glaucoma drainage devices.
The Molteno3® is designed to enhance surgical utility and optimize clinical outcomes
The novel design elements of the Molteno3® enable it to achieve the same clinical outcomes as larger plate alternatives via a shorter, simplified surgical procedure.1
1. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50.
At just 0.4mm, the Molteno3® is the slimmest plate on the market and slides easily between tissue planes and adjacent extraocular muscles.
The Molteno3® S‑Series is up to 15 minutes faster to implant than larger plate alternatives.3
3. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50.
References 1. Dixon MW, Moulin TA, Margolis MS, et al. Comparative Outcomes of the Molteno3 and Baerveldt Glaucoma Implants. Ophthalmol Glaucoma. 2020;3(1):40 – 50. 2. Sun, PY et al. Diplopia in Medically and Surgically Treated Glaucoma Patients Ophthalmology. 2017 Feb; 124(2): 257 – 262. 3. Nour-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed glaucoma valve. Am J Ophthalmol 2003;136:1001 – 8. 4. Hong C‑H, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: A systematic literature review and current controversies. Surv. Ophthalmol 2005; 50:48 – 60 5. Molteno AC, Fucik M, Dempster AG, Bevin TH. Otago Glaucoma Surgery Outcome Study: factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmology. 2003 Nov 30;110(11):2198 – 206) 6. Välimäki, J O et al. Molteno3 Implantation as Primary Glaucoma Surgery. J Ophthalmol. 2014; 2014: 167564. 7. Sheybani et al. Differences In Intraocular Pressure and Medication Usage Between The Baerveldt And Molteno Glaucoma Drainage Devices. 29th Annual Meeting of the (AGS), 2019 8. Molteno ACB, et al. Long-Term Results of Primary Trabeculectomies and Molteno Implants for Primary Open-Angle Glaucoma. 2011. Arch Ophthalmol; 129(11):1444 – 1450
Indications: The Molteno3® Glaucoma Drainage Device is indicated to reduce intraocular pressure in neovascular glaucoma and glaucoma where medical and conventional surgical treatments have not been successful, to control the progression of disease.
Contradictions: Patients with the following conditions may not be suitable candidates for the Molteno3® Glaucoma Drainage Device: 1. intraocular infection, 2. rheumatoid arthritis, scleritis and immune corneal melt syndromes, 3. Scleral Buckle.
Complications: Possible complications with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: choroidal detachment, retinal detachment, expulsive haemorrhage, pupillary block, lenticulo-ciliary block, shallowing and flattening of the anterior chamber, intraocular infection, diplopia, loss of central vision, hypotony and corneal endothelial damage.
Adverse events: Possible adverse events with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: corneal endothelial damage when the tube touches the corneal endothelium, breakdown of the tissues overlying the bleb, diplopia when the placement of the implant interferes with the action of the extraocular muscles, corneal decompensation, progression of lens opacities, cystoid macular oedema, retinal detachment and intraocular infection.
Precautions: Caution should be taken with supra-Tenon implantation; erosion of the conjunctiva is known to result from the raised edge of the oval pressure ridge (Molteno3® G‑Series).
This website uses cookies to ensure you get the best experience on our website. The cookies do not store any personalised information. Learn More
